A phase II study of omacetaxine mepesuccinate for patients with higher ‐risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

American Journal of Hematology,Volume 0, Issue ja, -Not available-.

Source: American Journal of Hematology - October 17, 2018 Category: Hematology Authors: Nicholas J. Short, Elias Jabbour, Kiran Naqvi, Ami Patel, Jing Ning, Koji Sasaki, Graciela M. Nogueras ‐Gonzalez, Prithviraj Bose, Steven M. Kornblau, Koichi Takahashi, Michael Andreeff, Gabriela Sanchez‐Petitto, Zeev Estrov, Courtney D. Source Type: research